|Bid||1.0100 x 0|
|Ask||1.0200 x 0|
|Day's Range||1.0000 - 1.0700|
|52 Week Range||0.6000 - 1.5000|
|Beta (3Y Monthly)||3.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...
EDMONTON, Alberta, March 14, 2019 -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce that it has begun production.
The reviewed financial statements and Management’s Discussion & Analysis are available under the Company’s profile at www.SEDAR.com. This reserve of cash will allow Radient to execute on its previously announced physical and operational expansions in Edmonton and Germany (summarized in greater detail below). Radient’s current total debt is CAD $10M and the Company was granted its Standard Processing License from Health Canada on February 1, 2019.
WKN: A1C4WM) today announced that it has agreed to terms to acquire a 51% ownership interest in Gaia Pharm Lda ., a license applicant in Portugal , to establish a local facility to produce medical cannabis and derivative products. The company will be renamed "Aurora Portugal Lda".
EDMONTON, Alberta, Feb. 22, 2019 -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce it has filed an additional 17.
WKN: A1C4WM) announced today that Michael Singer , previously Chairman of the Board, has been appointed Executive Chairman of the Board of Directors. The Company also announced that independent director Ronald Funk has been named Lead Independent Director and Margaret ("Sha n") Atkins has been appointed as a new independent director and Chair of the Audit Committee.
WKN: A1C4WM) today announced that the Company's construction of a 300,000 square foot expansion at the Edmonton International Airport is progressing well. The new facility, named Aurora Polaris, is intended to serve as Aurora's centre of excellence for the industrial-scale production of higher margin, value added products, such as edibles which Health Canada regulations propose to permit from October 2019 onwards.
Aurora Cannabis Announces Confirmed Time for its Conference Call to Discuss Second Quarter 2019 Results
Cannabis firm AgraFlora Organics International (CSE: AGRA) (OTCPK: PUFXF) – formerly PUF Ventures – said that Natures Hemp Corp., a spin-off company from PUF Ventures that focuses on biotechnology and consumer products, has moved its hemp-based coffee creamer project to the second phase of the development process. The non-dairy coffee creamer will be made using […] The post Cannabis Stock News Daily Roundup February 5 appeared first on Market Exclusive.
Canadian cannabis producer Aurora Cannabis Inc (NYSE: ACB) announced Monday that Health Canada has granted its extraction technology partner Radient Technologies Inc (OTC: RDDTF) a standard processing license. Radient identified a process to extract cannabis and hemp at large-scale volumes without risking the quality of the plant, according to Aurora. Aurora said it became aware of Radient's technology and its potential to disrupt the market in 2016.
OTCQX: RDDTF) announces today the following changes to its Board of Directors. Radient believes Mr. Cleiren will be a valuable addition to the Company as it moves forward with the commercial production of cannabinoid extracts and products, along with the global expansion of its operations. Concurrent to the appointment of Mr. Cleiren to Radient’s Board of Directors, the Company also announces that Mr. Terry Booth is stepping down from Radient’s Board of Directors, effective today.
In 2016, Aurora identified Radient's proprietary extraction technology (MAP™) as potentially disruptive for the cannabis industry due to its ability to achieve much higher throughputs than is possible with existing benchmark technologies, as well as its efficiency and ability to preserve the full spectrum of cannabinoids and terpenes found in the source material.
OTCQX: RDDTF) is pleased to announce it has received its Standard Processing License from Health Canada under the new Cannabis Act regulations, which came into force on October 17, 2018. Processing of cannabis biomass in order to extract cannabinoids including CBD and THC will now begin at Radient’s recently expanded manufacturing facility (“Edmonton I Facility”) located at 4035 101 St NW in Edmonton, Alberta. This will create new revenue streams for the Company, as it begins supplying premium grade cannabis extracts and cannabinoid ingredients to its partners, including Aurora Cannabis Inc.
"These convertible notes offer Aurora the flexibility and optionality to settle the entire principal amount of the notes in the future for cash, shares, or combination thereof," said Aurora CEO Terry Booth . Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth.
The Company will issue US$300.0 million aggregate principal amount of notes, or US$345.0 million aggregate principal amount if the initial purchasers' over-allotment option is exercised in full. Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth.
Aurora also intends to grant to the initial purchasers of the notes an option to purchase up to an additional US$37.5 million aggregate principal amount of notes. Aurora expects to use the net proceeds from the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company's accelerated growth. The final terms of the notes will be determined by Aurora and the initial purchasers.